Wednesday, October 14, 2026

CBOE Bullish Momentum With A 23% Rise In The Last 21 Sessions

ViaNews Editorial Team

September 29, 2023

CBOE Bullish Momentum With A 23% Rise In The Last 21 Sessions

(VIANEWS) - CBOE (VIX) has been up by 23.21% for the last 21 sessions. At 04:10 EST on Friday, 29 September, CBOE (VIX) is $16.72.

About CBOE's yearly highs and lows, it's 7.66% up from its 52-week low and 52.3% down from its 52-week high.

Volatility

CBOE's last week, last month's, and last quarter's current intraday variation average was 0.32%, 1.17%, and 4.23%, respectively.

CBOE's highest amplitude of average volatility was 5.72% (last week), 4.65% (last month), and 4.23% (last quarter), respectively.

News about

  • According to Zacks on Wednesday, 27 September, "Subramanian highlights that just five companies now account for 25% of the S&P 500 index.", "In a recent note to clients, Bank of America raised its year-end target for the S&P 500 from 4,300 to 4,600, indicating a potential 3% upside from the current S&P 500 levels. "
  • According to MarketWatch on Wednesday, 27 September, "It has run up 28.8% year to date, while the S&P 500 index SPX has gained 11.3%."
  • According to MarketWatch on Wednesday, 27 September, "The stock rose 1.6% premarket but is down 8.8% in the year to date, while the S&P 500 SPX has gained 11.3%."
  • According to DailyForex on Wednesday, 27 September, "The tech-heavy Nasdaq 100 and S&P 500 indices have crashed by more than 8% from their highest points this year."
  • According to MarketWatch on Wednesday, 27 September, "For more read: has fallen 95% in the year to date, while the SPDR S&P Biotech ETF XBI has fallen 12% and the S&P 500 SPX has gained 11.3%"

More news about CBOE (VIX).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com